Pds Biotechnology Corp Stock In The News

PDSB Stock  USD 1.25  0.10  8.70%   
Our overall analysis of PDS Biotechnology's news coverage and content from conventional and social sources shows investors' bearish mood towards PDS Biotechnology Corp. The specific impact of PDS Biotechnology news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of PDS Biotechnology's overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using PDS Biotechnology headlines in addition to utilizing other, more conventional financial analysis modules. Check out PDS Biotechnology Backtesting and PDS Biotechnology Hype Analysis.

PDS Biotechnology Today Top News and Investor Outlook

Investing News at Macroaxis
PDS Biotechnology stock advances as Phase 2 trial meets expansion criteria
https://www.investing.com/news/analyst-ratings/pds-biotechnology-stock-advances-as-phase-2-trial-meets-expansion-criteria-93CH-4131850
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
https://www.globenewswire.com/news-release/2025/06/09/3095789/37149/en/PDS-Biotech-to-Host-Key-Opinion-Leader-Event-to-Discuss-Versamune-HPV-for-the-Treatment-of-HPV16-HNSCC.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Announces Positive Extended ...
https://www.globenewswire.com/news-release/2025/05/22/3087179/37149/en/PDS-Biotech-Announces-Positive-Extended-Follow-Up-Data-for-VERSATILE-002-and-Additional-Trials-Evaluating-Versamune-HPV-to-be-Presented-at-the-2025-American-Society-of-Clinical-Onc.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
https://www.globenewswire.com/news-release/2025/05/20/3084788/37149/en/PDS-Biotech-to-Participate-at-the-A-G-P-Virtual-Annual-Healthcare-Company-Showcase.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2025/05/09/3078527/37149/en/PDS-Biotechnology-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Bullish
Macroaxis News: globenewswire.com
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
https://www.globenewswire.com/news-release/2025/04/23/3066573/37149/en/PDS-Biotech-Announces-Multiple-Abstracts-Selected-for-Presentation-at-the-2025-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025â„¢ Annual Meeting
https://www.globenewswire.com/news-release/2025/04/16/3062470/37149/en/PDS-Biotech-Announces-Preclinical-Influenza-Data-to-be-Presented-in-Symposium-at-IMMUNOLOGY2025-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
https://www.globenewswire.com/news-release/2025/04/08/3057569/37149/en/PDS-Biotech-Announces-PDS01ADC-Clinical-Data-to-be-Presented-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2025.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
https://www.globenewswire.com/news-release/2025/03/27/3050442/37149/en/PDS-Biotech-Reports-Full-Year-2024-Financial-Results-and-Provides-Clinical-Programs-Update.html
 Neutral
Macroaxis News: globenewswire.com
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
https://www.globenewswire.com/news-release/2025/03/25/3048687/37149/en/PDS-Biotech-Leadership-to-Present-at-2025-CAGLA-NeauxCancer-Conference.html
 Neutral

PDS Biotechnology Corp Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide PDS and other traded companies coverage with news coverage. We help investors stay connected with PDS headlines for the 25th of July to make an informed investment decision based on correlating the impacts of news items on PDS Stock performance. Please note that trading solely based on the PDS Biotechnology Corp hype is not for everyone as timely availability and quick action are needed to avoid losses.
PDS Biotechnology's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help PDS Biotechnology Corp investors visualize upcoming and past events in order to time the market based on PDS Biotechnology Corp noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PDS Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PDS Biotechnology's short interest history, or implied volatility extrapolated from PDS Biotechnology options trading.
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out PDS Biotechnology Backtesting and PDS Biotechnology Hype Analysis.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.94)
Return On Assets
(0.38)
Return On Equity
(1.19)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.